SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences to purchase API business of Sterling Biotech

17 Sep 2024 Evaluate

Zydus Lifesciences has received approval from Board of Directors for Business Transfer Agreement (BTA) to purchase the Active Pharmaceutical Ingredients (API) business of Sterling Biotech (SBL) on a going concern basis, on slump sale basis, without values being assigned to individual assets and liabilities, on cash-free and debt-free basis at a pre-defined lump-sum consideration of Rs 84.00 crore, subject to certain conditions precedent and closing date adjustments as provided in the BTA, with effect from such date, and in such manner and on the terms and conditions as mentioned in the BTA.

The Target Business of SBL consists of a portfolio of fermentation-based API products like Lovastatin, Daunorubicin, Doxorubicin and Epirubicin.

The Company is looking for fermentation-based API business with manufacturing facility given the high entry barriers and attractive margin profile of such business. The Company has a dedicated fermentation lab that is focusing on the development of new products. Building a new plant through the greenfield route could be more expensive and time taking. 

With the said acquisition of the Target Business of SBL, the Company will be in a position to meet its strategic and commercial objectives. The Board of Directors of the Company at their meeting held on September 17, 2024 have approved the same.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

942.55 3.35 (0.36%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×